Introduction {#S1}
============

Alzheimer's disease (AD) is a progressive age-related neurodegenerative disorder characterized by cognitive and psychiatric symptoms, such as memory and cognitive impairments, behavioral abnormalities, disorientation, and circadian rhythms and sensorial disturbances ([@B62]). Although environmental factors have been implicated in AD ([@B55]), genetics plays a key role in disease's pathogenesis. Two main forms of AD can be distinguished: the familial autosomal dominant form (fAD) and the sporadic counterpart (sAD); sAD is further divided into early onset (average onset age \<65 yo) and late-onset (average onset age \>65 yo). Mutations in three key genes associated with the amyloid metabolism, namely amyloid precursor protein, presenilin 1, and presenilin 2 are linked to fAD ([@B27]). However, fAD accounts only for less than 1% of the cases ([@B96]), and the majority of AD cases are sporadic, though a genetic susceptibility has been identified in those individuals carrying the apolipoprotein E gene ([@B107]; [@B39]). While the main scientific hypothesis underlying Alzheimer's pathogenesis is amyloid-driven ([@B47]; [@B46]; [@B108]), it is still debated whether alterations in tau protein's function are a consequence of an impaired amyloid metabolism or it may act by itself, or synergistically to amyloid protein, to trigger the pathology ([@B78]; [@B103]).

Albeit the genetic factors and individual susceptibilities, the AD brain displays a spread tissue degeneration with dense extracellular deposits of toxic amyloid-β (Aβ) oligomers and hyperphosphorylated tau-enriched intracellular tangles. Mitochondrial dysfunction, diffuse reactive oxygen species, and neuroinflammatory response are, among other, tissue, and cellular manifestations ([@B25]). Diagnostic methods to assess the presence of AD biomarkers relies on brain imaging techniques, such as computed tomography, magnetic resonance index, and positron emission tomography in combination with the analysis of cerebrospinal fluid with high cost and invasiveness ([@B54]). Additional non-invasive and less expensive approaches are also under validation to support an early diagnosis of AD. Recently, novel diagnostic approaches are focusing on the imaging of patients' retina and eye microvasculature ([@B87]; [@B44]). The rationale for exploiting such tissue relies on the common embryological origin of the retina and the brain ([@B8]; [@B17]; [@B51]). Remarkably, anatomical and functional alterations, such as the thinning of the ganglion cell and retinal nerve fiber layers ([@B83]; [@B104]), the presence of protein aggregates, and the glial activation ([@B56]; [@B24]; [@B42], [@B43]) can be detected in the post-mortem evaluation of retinae of AD patients and humanized AD animal models, thus strengthening the idea that the retina could be exploited in early AD diagnosis.

Moreover, visual deficits, including difficulty reading ([@B93]), depth perception ([@B73]), and color recognition ([@B23]), are also reported in the early stages of AD. All these efforts aim to find specific biomarkers and tools for AD diagnosis at earlier stages, possibly when synapses and neuronal functions are not yet compromised, allowing pharmacological and clinical interventions ([@B35]). In this context, understanding the biological basis of AD progression remains a major scientific challenge, largely because of the complexity of the human brain cell interactions. Indeed, the lack of appropriate preclinical models of the human neurodegenerative pathologies, and in particular AD, hinders the understanding of pathological mechanisms and consequently the development of effective and safe diagnostic procedures and therapies.

From Humanized Mouse Models Toward Stem Cell-Based 3D *in vitro* Approaches {#S1.SS1}
---------------------------------------------------------------------------

While more than 200 functional transgenic rodent models have been generated ([@B45]), they only partially recapitulate pathogenic traits of AD, and to date, none of the potential drug candidates screened up to now has shown effective therapeutic outcomes in humans, making the translation into clinics of these drugs controversial ([@B63]). Thus, the continuous development of novel *in vitro* disease models, which more comprehensively recapitulate hallmarks of AD, represents an important research strategy that may enable to accelerate the molecule screening process before testing a lead candidate *in vivo* on transgenic rodent AD models.

The identification of the key molecular factors (Sox2, Klf4, c-Myc, and Oct3/4) necessary for bringing back to stemness an adult somatic cell (the so-called "Yamanaka factors") has posed the basis for a revolution in the field of *in vitro* human disease models ([@B67]). iPSCs represent a pluripotent stem cell class capable of differentiating, in response to specific small molecule stimuli, into each of the three embryonic germ layers and therefore, in principle, to any terminally differentiated cell type ([@B102]). These cells exhibit features similar to those found in embryonic stem cells (ESCs) and can be potentially derived from different somatic cell types. Before iPSCs, the development of stem cell-based *in vitro* models relied mostly on mouse ESCs and in some limited cases on human ESCs, although, in the latter, the poor availability due to legal and ethical constraints has negatively affected their usage ([@B94]). Thus, the use of these new stem cells has fostered the efficient generation of versatile human-based cellular models to study disease-relevant genome-specific alterations preventing the ethical concerns associated with the use of human ESCs.

The advancements in three dimensional (3D) culturing approaches ([@B7]; [@B29]) together with the regenerative potential of iPSCs have driven the generation of a plethora of new protocols for creating 3D micro-physiological systems *in vitro* to exploit as an alternative and complementary approach to humanized animal models for the study of species- and patient-specific features ([@B16]).

Several newly designed 3D cell culture methods have been proposed, spanning from cell-laden 3D scaffolds ([@B84]) to induced pluripotent stem cell (iPSC)-based cerebral organoids ([@B41]) and 3D bioprinting ([@B97]). Cell-laden structures can be realized by encapsulating neuronal cells within a variety of materials ([@B57]; [@B69]), either natural and synthetic, that might replicate some pivotal features of the native extracellular matrix (ECM), including stiffness and ECM-dependent pathways ([@B28]). While the stiffness of plastic can hardly replicate the mechanical environment provided by the brain ECM, the use of biocompatible ECM-like gels (hydrogels) may provide several benefits ([@B5]). Hydrogels, such as collagen, gelatin, hyaluronic acid and similar, provide a tissue-like water content, and tunable biochemical and mechanical properties, thus supporting the generation of tailored 3D microenvironments in which cells can self-organize in distinct tissue architectures ([@B12]). Additionally, the biological stimuli coming from the surrounding 3D microenvironment contribute to the long-lasting survival, and functional maturation of cells typically challenging to be cultured *in vitro*, such as neurons. For instance, in 3D neural constructs, the increased dimensionality allows a more compliant physiological cell-cell interactions between neurons, thus limiting spatial overlap during neurite elongation and branching ([@B81]). Moreover, several studies reported a less synchronous bursting activity and a relatively higher level of random spiking when comparing 3D neuronal cultures to conventional 2D cultures ([@B31]; [@B98]). Frega and collaborators speculate that a wider cellular interaction within 3D cultures leads to a broad desynchronization of network activity, thus producing bursting activities only in specific neuronal subpopulations ([@B34]). In support of this hypothesis, locally synchronized electrophysiological patterns are also observed in other experimental models, such as acute rodent brain slices ([@B10]; [@B9]), where are assumed to play an essential role in the maturation of developing functional circuitry. However, experimental observations in the field are still controversial and there is not a unified theory behind the nature and function of synchronous and asynchronous network activities.

Among this variety of 3D culture systems, a promising *in vitro* tissue-like 3D platform is represented by the brain and retinal organoids. Organoids are stem cell-derived cellular aggregates ([@B21]), which, starting from a selected cluster of iPSCs, can acquire morphological and functional features as well as gene-expression patterns, similar to those found in the corresponding native structures ([@B59]). Indeed, since the first organoid protocol in 2009, a lot of effort has been made for generating organoids that mimic a wide range of human organ types, and nowadays an extensive scientific literature demonstrates their potentiality in modeling some human diseases ([@B95]). Due to the greater diversity of cell composition and functions, organoids have the potential to create physiological cellular environments for modeling the biology of the human central nervous system (CNS) and might bridge the need for an efficient, reproducible and reliable *in vitro* 3D model for the conduction of preclinical high throughput drug screening directly on patient-derived tissue-like samples ([@B52]; [@B60]).

Alzheimer's Disease in a Dish: Patient-Specific Brain and Retinal Organoids {#S1.SS2}
---------------------------------------------------------------------------

Cerebral organoids derived from human iPSCs can autonomously recapitulate the 3D architectural arrangement of the brain and spontaneously generate discrete brain regions including the dorsal forebrain, the hippocampus, and the retina ([Figure 1](#F1){ref-type="fig"}).

![Three-dimensional biological complexity of a human iPSC-derived whole-brain organoid **(left)** and enlarged image of a representative cortical layer organization **(right)**. Immunostaining at day 50 of iPSC-derived brain organoid reveals the presence of a primitive cortical stratification containing early born deep-layer neurons (TBR1, red; CTIP2, green). Pan-neuronal dendrites structures are stained with MAP2 (white) and nuclei are stained with DAPI (blue). Scale bars = 500 microns (image on the **left**) and 50 microns (image on the **right**). Multiarea acquisition was performed with a laser scanning confocal microscope using a 60× magnification objective.](fnins-14-00655-g001){#F1}

Different methods to generate organoids have been already reported in the literature with different structural complexity and cellular diversity ([@B70]; [@B86]; [@B58]; [@B38]). Among the established 3D organoids, two main categories can be identified: (i) self-patterned organoids, based only on the intrinsic capacity of stem cells to self-differentiate and assemble ([@B61]) in native-like structures, and (ii) patterned organoids, which exploits the use of small molecules to drive and lead the formation of specific brain regions ([@B70]; [@B52]; [@B86]).

Lancaster and Knoblick first described the development of cerebral organoids from human iPSCs ([@B60]). Growing spherical iPSC aggregates in suspension, known as the embryonic bodies (EBs), enable the generation of radially organized neuroepithelial buds that mimics the cell-cell interactions observed during early embryogenesis and, supporting their growth through their embedding into ECM droplets, it is possible sustaining their apicobasal expansion. Over time, heterogeneously terminally differentiated cell types are generated and organized in well spatially defined structures that resemble human brain regions including dorsal forebrain layering.

Nevertheless, the generation of these cytoarchitectural structures relies mainly on the self-patterning and intrinsic mechanisms of stem cells, and the high variability, in terms of structure distribution, complexity, and maturation, remains one of the major limitations affecting this technology. This randomness influences the reproducibility of cellular responses to specific stimuli, thus generating a significant variance of collected data even on organoids belonging to the same iPSC line and compromising the wide exploitation of such models in clinical research ([@B61]). A recent work of Lancaster's group demonstrated that combining self-patterned organoids with bioengineered microfilaments, such as poly(lactide-co-glycolide) copolymer (PLGA) fibers, the overall reproducibility of internal cytoarchitectures of the model can be improved, lowering the number of non-neural identities within the organoids ([@B58]). However, despite those improvements, the inter-organoids variability is not challenged, and it remains an important drawback.

On the other hand, the application of synthetic morphogens or exogenous small molecules, as in the case of patterned approaches, influences and tunes the iPSC fate to a specific range of neurogenic cell types, introducing specific morphogenetic constraints that result in a steady proportion of cell types generated within organoids and batches of differentiation ([@B90]; [@B99]; [@B111]). However, if from one side patterned organoids display a similar gene-expression diversity ([@B105]), they fail to efficiently generate highly expanded cortical structures and thus may not represent the ideal platform for modeling morphological and structural changes that occur in neurological disorders typical of the adult brain as neurodegenerative diseases ([@B53]).

Thanks to these remarkable features, brain organoids are finding a wide range of applications for the study of diseases affecting the human brain development, such as congenital brain malformation and neurological disorders, including age-related neurodegenerative diseases ([@B2]; [@B82]). Recently, the use of iPSC-derived cerebral organoids led to replicate *in vitro* some molecular determinants of Alzheimer's disease, such as the Aβ and tau pathology and the subsequent synapses dysfunction ([@B40]). Independent studies reported that treatment with γ-secretase or β-secretase inhibitor compounds was able to partially inhibit the production of toxic Aβ and to reduce the hyperphosphorylation of tau proteins, suggesting the Aβ-driven tauopathy theory ([@B64]; [@B91]). Mook-Jung and collaborators reported the discovery of CDK-504 ([@B19]), a selective histone-deacetylase 6 inhibitor, which dramatically enhances the proteasome degradation pathway of pathological tau in AD patient-derived brain organoids and rescues synaptic deficits. The use of brain organoids can also accelerate Aβ accumulation in culture, thus facilitating the characterization of the associated cellular and molecular events ([@B91]). Indeed, the presence of a 3D matrix surrounding the cells may constrain the diffusion of pathologic proteins in the culture media, allowing their distribution in confined areas, and resulting in local protein aggregation and accumulation ([@B20]; [@B84]). For instance, a consistent increase of Aβ42 fragment secretion and Aβ42/Aβ40 ratio, similar to pathological phenotypes observed in transgenic animal models, has been found in AD cerebral organoids ([@B88]). Moreover, co-cultures of regionalized organoids ([@B6]; [@B11]; [@B110]), which resemble distinct areas of the brain (i.e., dorsal forebrain, ventral forebrain, hippocampus), would allow the modeling of important aspects of human brain regions interaction, which might be exploited to investigate the spreading of toxic protein aggregates in the whole CNS.

Interestingly, as part of the CNS, the retina has demonstrated some pathological processes that occur in the brain during neurodegeneration. In AD patients, relevant visual deficits ([@B77]) sometimes appear before the first neurological symptoms, making the retina a potential *in vivo* tool to use for monitoring the onset and progression of the AD neurodegeneration ([@B66]). Therefore, the development of *in vitro* engineered tissue-like constructs, such as retinal organoids, that better approach the retinal tissue and physiology undergoing AD pathogenesis is reasonably also under evaluation ([@B4]). As for brain organoids, independent pioneering works reported the *in vitro* generation of eye structures, such as retina ([@B15]), retinal pigmented epithelium ([@B92]), lens ([@B75]), and cornea ([@B33]). Sasai's work demonstrated that the formation of the optic cup-like structure could be achieved from mouse and human ESCs *in vitro* ([@B30]; [@B76]). Similarly to whole-brain organoids, culturing iPSC-derived EBs in predetermined conditions generates 3D optic cup-like structures together with stratified neural retinal cell subtypes and progenitors. After this seminal work, several protocols have been proposed to drive the differentiation of human iPSC toward retinal organoids ([@B72]). Current retinal differentiation protocols can produce most relevant retinal cell types in laminated fashion with a variable efficiency in generating functional photoreceptors ([@B113]) to retinal ganglion cells ([@B79]), and overall mature retinal tissues. Indeed, retinal organoids do not routinely exhibit a complete maturation of the tissue with morphological or electrophysiological features characteristic of the adult retina *in vivo*. Several studies have successfully proven the utility of such *in vitro* models in some retinal degenerative diseases, such as glaucoma ([@B79]) and retinitis pigmentosa (RP; [@B36]). Retinal organoids have been also exploited as a tool to investigate retinal ganglion cell's (RGCs) physiology, as a means to assess RGC's regeneration potential and neuroprotective effect of new therapeutics ([@B32]). However, while patient-specific retinal organoids represent a functional model for evaluating biological processes underlying the eye development and disease *in vivo*, such models are still not exploited in studies of neurodegenerative diseases of the CNS, such as in AD.

Future Directions of the Organoid Technology {#S1.SS3}
--------------------------------------------

Recently, organoids opened an avenue to generate a versatile scaled-down version of brain and retina tissues, which may significantly help the study of the pathogenic mechanisms hiding behind neurodegenerative disorders, such as in AD, and foster the design and high-throughput screening of candidate molecules toward the development of a personalized diagnostic and therapeutic approach ([Figure 2](#F2){ref-type="fig"}).

![Schematic representation of human stem cell-based *in vitro* systems for neurodegenerative diseases. The iPSC building blocks (1) are obtained from cell reprogramming of somatic cells from patients or healthy donors. iPSC-derived neuronal cultures, either in the form of 2D and 3D cell cultures (2), are generated to reproduce the biological complexity of human tissues *in vitro*. Cerebral and retinal organoids (3) can reproduce *in vitro* cortical and retinal features, with all their structural and functional components, thus becoming promising patient-specific platforms for the study of neurodegenerative pathologies, such as Alzheimer's disease (4). [Figure 2](#F2){ref-type="fig"} was assembled using images downloaded from Servier Medical Art, licensed under a Creative Common Attribution 3.0 Generic License. <http://smart.servier.com/>.](fnins-14-00655-g002){#F2}

The use of patient-derived iPSC-based retinal and brain organoids together with advanced gene-editing techniques might provide a simplified sight into the mechanisms underlying AD-related alterations, predicting more comprehensive clinical outcomes and possibly overcoming some limitations imposed by humanized animal models. Importantly, preserving the genetic and epigenetic patient-specific background may provide a striking strategy for understanding such neurodegenerative mechanisms and constitutes an opportunity to identify pathology-related hallmarks not otherwise recognizable during medical imaging evaluation or post-mortem tissue observations ([@B37]).

Nonetheless, the iPSC-based 3D organoid system is yet in its infancy, and, up to now, it appears to be not devoid of disadvantages. Although iPSC technology could serve as a promising platform for disease modeling, their application in translational medicine remains poorly diffused, due to a not negligible donor-to-donor variability and concerns on the impact of virus-mediated reprogramming protocols when these cells are proposed for *in vivo* transplantation. Besides, iPSCs may display an increased genomic instability, carrying tumorigenic loci ([@B50]; [@B65]) and retaining epigenetic memory belonging to previous somatic fate ([@B89]).

A major issue for the use of such *in vitro* models in age-related neurodegenerative diseases is the optimization and validation of organoid's generation methods enabling a precise, reproducible, and relatively fast maturation of the organoid. Indeed, while aging drives numerous genetic alterations resulting in a continuously different cellular transcriptional profile ([@B68]), up to now organoids display an immature phenotype peculiar to the late fetal stage of the tissue ([@B13]). Unexpectedly, even though culturing retinal organoids for an extended period, they still present an incomplete maturation, thereby making it challenging to replicate aging-related phenotype in a dish. Different methods are under development to accelerate the maturation process in iPSC-derived neuronal cells ([@B74]). For instance, the application of chemical stressors into the culture media as hydrogen peroxide ([@B14]) and telomerase inhibitors ([@B106]) facilitates an aging-like phenotype in iPSC-derived neurons in 2D cell cultures. However, while it is reasonable to hypothesize to apply a similar strategy to accelerate the aging process in 3D retinal and brain organoids, it is not being exploited.

Furthermore, different cell types are involved in the AD pathogenesis, and neuron and synaptic loss are only the final events of a more complex picture. Unveiling the role of different brain and retinal cells (i.e., neurons, astrocytes, microglia, endothelial cells) may play a pivotal role in designing novel therapeutic approaches ([@B71]). To this end, 3D retinal and brain organoids provide an outstanding opportunity to explore cellular and subcellular functions within *in vitro* models that closely recapitulate the native 3D configuration of the human neural tissue. Another major challenge is represented by the role played by neuroinflammation in the neurodegenerative process ([@B48]) and how this could be carefully taken into account within *in vitro* AD models. Indeed, while microglia, the resident immune cells of the CNS, are recognized to strongly contribute to the AD onset and progression, they do not innately develop into brain and retinal organoids. Microglia deriving from the hematopoietic lineage, colonize brain tissue during embryonic development ([@B22]; [@B101]). Hence, their incorporation in brain and retinal organoids will be critical to dissect their contribution in the early stage of the disease and identify new and patient-specific therapeutic pathways ([@B100]). Recently, the innate generation of microglia cells within whole-brain organoids has also been reported ([@B80]), however, there is still little evidence regarding the reproducibility of the method and further characterization of this approach is required.

Similarly, vasculature and blood-retinal barrier (BRB) alterations are widely reported in AD retina and their investigation as possible diagnostic tools is under evaluation ([@B114]; [@B18]; [@B112]). Retinal tau protein plays a key role in regulating axonal transport and signaling in the retina ([@B49]). Reduced clearance of retinal Aβ and other neurotoxic substances contribute to BRB dysfunction and breakdown ([@B26]), inducing a persistent inflammatory state ([@B109]). Further, the BRB, similarly to the blood-brain barrier, can act as a checkpoint to the transit of many drugs, and for these reasons, *in vitro* vascularization of retinal organoids using endothelial cells might contribute to foster the identification and development of new molecular targets ([@B1]).

In conclusion, although there are yet several gaps to be filled before allowing the use of iPSC-based organoid technology in neurodegenerative and in translational studies, these *in vitro* platforms offer promising outlooks that might pave and foster the rapid growth of novel *in vitro* approaches to tackle AD ([@B85]). Moreover, alterations in retinal structure and function have been reported in other neurodegenerative disorders, such as Parkinson's Disease ([@B3]). Thus, elucidating the neurodegenerative mechanisms that underlie retinal impairments may provide not only useful insights regarding the brain disorders' onset and progression but also promising non-invasive tools for large-scale screening and monitoring brain diseases.

Author Contributions {#S2}
====================

CB and FC wrote the manuscript with support from LC. AS took the lead in editing the manuscript. AS and SD supervised the writing and conceived the idea. All authors provided critical feedback and helped to shape the manuscript.

Conflict of Interest {#conf1}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** The work was financially supported by the CrestOptics-IIT JointLab for Advanced Microscopy (to AS, CB, and SD) and the MARBEL Life2020 Grant (to SD and CB).

This work has received support from the Center for Life Nano Science -- Fondazione Istituto Italiano di Tecnologia (CLNS-IIT). We would like to thank Drs. Gianluca Cidonio, Ph.D. and Francesco Difato, Ph.D. for helpful discussions related to this manuscript. We also thank the Imaging Facility at the Center for Life Nano Science for support and technical advice.

[^1]: Edited by: Natalia P. Rocha, The University of Texas Health Science Center at Houston, United States

[^2]: Reviewed by: Stefan Liebau, University of Tübingen, Germany; Silvia Bolognin, University of Luxembourg, Luxembourg

[^3]: ^†^ORCID: Alessandro Soloperto, [orcid.org/0000-0002-8142-6059](https://orcid.org/0000-0002-8142-6059)

[^4]: ^‡^These authors have contributed equally to this work

[^5]: This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience
